Active, not recruitingPhase 2NCT02577926
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Studying Polycythemia vera
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- RWTH Aachen University
- Principal Investigator
- Steffen Koschmieder, Prof. Dr.RWTH University Hospital MK4
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 207 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2028
Study locations (23)
- Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie, Mannheim, Baden-Wurttemberg, Germany
- Universitätsklinikum Ulm Klinik für Innere Medizin III, Ulm, Baden-Wurttemberg, Germany
- Rems-Murr Klinikum Winnenden, Winnenden, Baden-Wurttemberg, Germany
- Studienzentrum Aschaffenburg, Aschaffenburg, Bavaria, Germany
- III. Medizinischen Klinik des Klinikums rechts der Isar der TU München, Müchen, Bavaria, Germany
- Klinikum Nürnberg Nord Medizinische Klinik 5, Nuremberg, Bavaria, Germany
- Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie, Hamburg, Hamburg, Germany
- Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik, Mainz, Hesse, Germany
- Uniklinik RWTH Aachen, Aachen, North Rhine-Westphalia, Germany
- Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III, Bonn, North Rhine-Westphalia, Germany
- Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik, Duisburg, North Rhine-Westphalia, Germany
- Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie, Düsseldorf, North Rhine-Westphalia, Germany
- Marienhospital, Düsseldorf, North Rhine-Westphalia, Germany
- Universitätsklinikum Essen Klinik für Hämatologie, Essen, North Rhine-Westphalia, Germany
- Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin, Minden, North Rhine-Westphalia, Germany
- +8 more locations on ClinicalTrials.gov
Collaborators
Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02577926 on ClinicalTrials.govOther trials for Polycythemia vera
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)MPN Research Foundation
- RECRUITINGPHASE2NCT07232290Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE2NCT06985147A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Disc Medicine, Inc
- RECRUITINGNCT06743035Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyiOMEDICO AG
- RECRUITINGNCT06752941LOW-PV ContinuationFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE3NCT06093672Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraItalfarmaco
- RECRUITINGPHASE1NCT06752746A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraMabwell (Shanghai) Bioscience Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06033586Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraProtagonist Therapeutics, Inc.